Literature DB >> 21156441

Procalcitonin levels in migraine patients.

Hale Turan1, Bahriye Horasanli, Murat Ugur, Hande Arslan.   

Abstract

OBJECTIVES: Migraine is a risk factor for ischemic stroke. Sterile vascular inflammation may develop during migraine attacks. This study aims to investigate procalcitonin (PCT) levels amongst migraine patients as they are important markers for infection and sepsis, but can also be found at elevated levels in various cases of inflammation.
METHODS: Eighty adult migraine patients participated in our study. Patients were initially separated into two main groups; Group-1 consisted of 34 patients who had migraines during the attack period. Group-2 consisted of 46 patients during the period in-between attacks. Afterwards, patients were further divided into four subgroups based on their aura status; Group-1a Migraine without aura, 27 patients during attack period, Group-1b Migraine with aura, 7 patients during attack period, Group-2a Migraine without aura, 40 patients during the period in-between attacks, Group-2b Migraine with aura, 6 patients during the period in-between attacks.
RESULTS: Average PCT levels in patients during attack periods were found to be higher than the average PCT levels of patients during the period in-between attacks. These elevated levels were determined to be statistically significant(p<0.01). Serum PCT levels of the patients with migraine without aura during the attack period were significantly higher than those of patients during the period in-between attacks(p<0.01).
CONCLUSIONS: Based on significantly high levels of PCT, our results support the idea that sterile inflammation plays a role in migraine pathogenesis. Further studies are necessary to understand whether PCT is a marker for ischemic stroke risk in patients who go through frequent migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21156441     DOI: 10.1017/s0317167100011161

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  8 in total

Review 1.  Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.

Authors:  Ann C Raddant; Andrew F Russo
Journal:  Expert Rev Mol Med       Date:  2011-11-29       Impact factor: 5.600

Review 2.  Role of Omics in Migraine Research and Management: A Narrative Review.

Authors:  Pragya Chaturvedi; Rahul Khan; Prachi Sahu; Abhilash Ludhiadch; Gagandeep Singh; Anjana Munshi
Journal:  Mol Neurobiol       Date:  2022-07-07       Impact factor: 5.682

3.  Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia.

Authors:  Ann C Raddant; Andrew F Russo
Journal:  Headache       Date:  2014-02-11       Impact factor: 5.887

4.  The change of neutrophils/lymphocytes ratio in migraine attacks: A case-controlled study.

Authors:  Keziban Ucar Karabulut; Tomris Ugur Egercioglu; Mehmet Uyar; Yildiz Ucar
Journal:  Ann Med Surg (Lond)       Date:  2016-07-27

5.  Purinergic Profiling of Regulatory T-cells in Patients With Episodic Migraine.

Authors:  Dilyara Nurkhametova; Igor Kudryavtsev; Olga Khayrutdinova; Maria Serebryakova; Rashid Altunbaev; Tarja Malm; Rashid Giniatullin
Journal:  Front Cell Neurosci       Date:  2018-09-25       Impact factor: 5.505

6.  Dynamics of inflammatory factors expression in ischemic brain tissue injury.

Authors:  Tonko Marinović; Silvio Bašić; Dominik Romić; Branimir Nevajda; Lovorka Đerek; Jurica Maraković; Marina Raguž
Journal:  Neurol Int       Date:  2019-12-02

Review 7.  Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.

Authors:  Tayla A Rees; Erica R Hendrikse; Debbie L Hay; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2021-07-27       Impact factor: 9.473

Review 8.  The omics in migraine.

Authors:  Luana Lionetto; Giovanna Gentile; Elisa Bellei; Matilde Capi; Donata Sabato; Francesco Marsibilio; Maurizio Simmaco; Luigi Alberto Pini; Paolo Martelletti
Journal:  J Headache Pain       Date:  2013-07-01       Impact factor: 7.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.